

W H O T e c h n i c a l R e p o r t S e r i e s

WHO Expert Committee on Leprosy

Eighth report

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

WHO Expert Committee on leprosy: eighth report.

(WHO technical report series ; no. 968)

1. Leprosy - epidemiology. 2. Leprosy - prevention and control. 3. Leprosy - therapy.
I. World Health Organization. II. WHO Expert Committee on Leprosy (2010: Geneva, Switzerland).
III. Series.

ISBN 978 92 4 120968 7

(NLM classification: WC 335)

ISSN 0512-3054

© World Health Organization 2012

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

Printed in Italy

Contents

WHO Expert Committee on Leprosy	v
Declarations of interest	vii
1. Introduction	1
2. Leprosy in the world	3
2.1 Assessment of global data	4
2.2 Global leprosy situation in 2010	4
2.3 New case detection	4
2.4 Trends in case detection	4
2.5 Profiles of new cases	8
3. Epidemiology	11
3.1 Definition of a leprosy case	11
3.2 Classification	12
3.3 Transmission, infection and incubation period	12
3.4 Infectiousness of leprosy	13
3.5 Risk factors	13
3.6 Interaction between HIV infection and leprosy	13
3.7 Geographical variations	14
4. Chemotherapy and management	17
4.1 Chemotherapy	17
4.1.1 Standard MDT regimens	17
4.1.2 Existing second-line antileprosy drugs	18
4.1.3 Promising new antileprosy drugs	19
4.1.4 Study on the uniform multidrug therapy regimen	21
4.1.5 Combined therapy with four weeks of daily ofloxacin and rifampicin	21
4.1.6 Treatment regimens for special situations	22
4.1.7 Relapses after multidrug therapy	22
4.2 Management of leprosy reactions and neuritis	23
4.2.1 Neuritis and nerve function impairment	23
4.2.2 Leprosy reactions	23
4.2.3 Treatment of leprosy reactions	24
4.3 Disability and rehabilitation	26
4.3.1 Magnitude of the problem	26
4.3.2 Disability grading for leprosy	26
4.3.3 Prevention, limitation and management of disabilities	26
4.3.4 Self-care	27
4.3.5 Community-based rehabilitation	27
5. Social issues	29
5.1 Equity, social justice and human rights	29
5.2 Gender	29
5.3 Enhancing the involvement of affected persons	30
5.4 Stigma and stigmatization	30



5.5	Counselling	31
5.6	Residential care	31
6.	Leprosy control and prevention	33
6.1	Improving the quality of leprosy services	33
6.2	Integrating leprosy control into general health services	34
6.3	Referral system	34
6.4	Building and maintaining national capacity	36
6.5	Community awareness and education	36
6.5.1	Community awareness	36
6.5.2	Information, education and communication	37
6.6	Improving case detection	38
6.6.1	Case-finding and case-holding	38
6.6.2	Delay in diagnosis	38
6.7	Special areas and populations	38
6.7.1	Areas with a high disease burden	38
6.7.2	Areas with a low disease burden	39
6.7.3	Underserved population groups	39
6.7.4	Urban areas	40
6.8	Contact surveillance	41
6.9	Treatment adherence	42
6.9.1	Flexible treatment	42
6.10	Supply management for multidrug therapy	42
6.11	Disease prevention	43
6.11.1	Primary BCG immunization	43
6.11.2	Immunoprophylaxis of contacts	44
6.11.3	Chemoprophylaxis of contacts	44
6.11.4	Next steps – prophylaxis strategy	45
6.12	Surveillance for drug resistance	45
6.13	Monitoring and evaluation	46
6.13.1	Indicators for monitoring	46
6.13.2	Independent evaluation of leprosy programmes	48
7.	Strategy for further reducing the disease burden due to leprosy – setting targets	49
7.1	Elimination of leprosy as a public health problem	49
7.2	New targets based on case detection and disability prevention	49
8.	Research priorities	51
9.	Conclusions and recommendations	53
	Acknowledgements	55
	References	57



WHO Expert Committee on Leprosy

Geneva, 12–19 October 2010

Members

Dr Y.A. Al-Qubati, Taiz University School of Medicine, Taiz, Yemen (*Rapporteur*)

Dr M.L.W. de Oliveira, Medical Professor, Rio de Janeiro Federal University, Rio de Janeiro, Brazil

Dr M. De Palma Caldas, Director, National Program for Control of Tuberculosis and Leprosy, Ministry of Health, Luanda, Angola

Professor P.E.M. Fine, Communicable Disease Epidemiology, Infectious and Tropical Disease Department, London School of Hygiene and Tropical Medicine, London, England

Dr M.D. Gupte, Retired Director, National Institute of Epidemiology, Indian Council of Medical Research, Chennai, India¹

Dr H.J.S. Kawuma, Medical Advisor, German Leprosy Relief Association, Kampala, Uganda

Dr T. Mori, Director Emeritus, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Kiyose, Tokyo, Japan

Dr H. Sansarricq, Former Head, Leprosy Programme, WHO, Geneva, Switzerland

Professor W.C.S. Smith, Head, Department of Public Health, Medical School, University of Aberdeen, Aberdeen, Scotland (*Chairman*)

Professor G. Zhang, Deputy Director, Institute of Dermatology and National Center for Leprosy Control, Nanjing, China

Temporary advisers

Professor P.J. Brennan, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA

Professor S. Cole, Global Health Institute, Department of Immunology, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

Professor J.H. Grosset, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Dr S.K. Noordeen, Former Director, Action Programme for Elimination of Leprosy, WHO, Geneva, Switzerland

¹ Unable to attend.

Mr J. Ramirez Jr., USA Coordinator and Board Member of International Association for Integration, Dignity and Economic Advancement (IDEA) and American Leprosy Missions, Houston, TX, USA

Representatives of other organizations

International Federation of Anti-Leprosy Associations (ILEP)

Mr D. Soutar, General Secretary, International Federation of Anti-Leprosy Associations, London, England

International Leprosy Association (ILA)

Dr M. Virmond, President, International Leprosy Association, Bauru, Brazil

Representative of Mr Y. Sasakawa, WHO Goodwill Ambassador for Leprosy Elimination

Professor K. Kiikuni, Chair, Sasakawa Memorial Health Foundation, Tokyo, Japan

Secretariat

Dr M.T. Htoon, Team Leader, WHO Global Leprosy Programme, WHO Regional Office for South-East Asia, New Delhi, India (*Secretary*)

Dr V. Pannikar, Temporary International Professional, WHO Global Leprosy Programme, WHO Regional Office for South-East Asia, New Delhi, India

Declarations of interest

Members of the WHO Expert Committee on Leprosy reported the following:

Dr Y.A. Al-Qubati reported that he provides supervision to the Leprosy Control Programme of Yemen. For these services, he receives an honorarium from the German Leprosy and TB Relief Association (GLRA), which is a nongovernmental organization.

Professor S. Cole reported that, through his previous employment at Institut Pasteur, he is a named inventor on a patent for antimycobacterial compounds that have antileprosy activity in a murine model. The patent in question has been licensed to the company Alere Technologies GmbH, for whom Professor Cole acts as a consultant, with an annual income of approximately € 20 000. He currently teaches leprosy-related subjects at the Ecole Polytechnique Fédérale de Lausanne.

Professor P.E.M. Fine reported that he is on the Editorial Board of the journal *Leprosy Review*. He also reviews grants related to leprosy research for the Order of Malta, for which he has received an honorarium payment for the past four years.

Professor J.H. Grosset reported that he is a member of the Scientific and Medical Commission of Association Raoul Follereau of France as well of the United States of America/Japan Panel for Leprosy and Tuberculosis Research. He receives no remuneration for either position.

Dr H.J.S. Kawuma reported that he works as a Medical Adviser in Uganda for the German Leprosy and TB Relief Association (GLRA), which is a nongovernmental organization.

Dr S.K. Noordeen reported that he was involved in the preparation of the background documents for this meeting under an Agreement for the Performance of Work (APW) with WHO; this APW expired on 10 October 2010.

Mr J. Ramirez Jr reported that he serves as Managing Editor of *The Star*, an international magazine put together by persons affected by leprosy. He also serves as the United States of America Coordinator for the International Association for Integration, Dignity and Economic Advancement (IDEA), an organization comprising primarily persons affected by leprosy. He receives no remuneration for either position.

Professor W.C.S. Smith reported that he is President of the Leprosy Mission International and Chair of the Technical Commission of the International Federation of Anti-Leprosy Associations. He receives no remuneration for either position.



预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28484

